Cardiomyocyte-Specific Overexpression of HEXIM1 Prevents Right Ventricular Hypertrophy in Hypoxia-Induced Pulmonary Hypertension in Mice

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Yoshikawa, Noritada ^a   Shimizu, Noriaki ^a   Maruyama, Takako ^a   Sano, Motoaki ^b   Matsuhashi, Tomohiro ^b   Fukuda, Keiichi ^b   Kataoka, Masaharu ^b,c   Satoh, Toru ^c   Ojima, Hidenori ^d   Sawai, Takashi ^e   Morimoto, Chikao ^f   Kuribara, Akiko ^a   Hosono, Osamu ^a   Tanaka, Hirotoshi ^a  

^a THE UNIVERSITY OF TOKYO   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^e IWATE MEDICAL UNIVERSITY   (Japan)

^f JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN; HEXAMETHYLENE BIS ACETAMIDE INDUCIBLE PROTEIN 1; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; RNA BINDING PROTEIN; RNA POLYMERASE II; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ENLARGEMENT; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HEART DILATATION; HEART MUSCLE CELL; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HUMAN TISSUE; HYPOXIA; MALE; MOUSE; MUTANT; NEWBORN; NONHUMAN; PULMONARY HYPERTENSION; RAT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANOXIA; DISEASE PROGRESSION; ENDOTHELIN-1; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; ORGAN SPECIFICITY; POSITIVE TRANSCRIPTIONAL ELONGATION FACTOR B; RATS; RNA-BINDING PROTEINS;

ADENOVIRIDAE; MUS; MUS MUSCULUS; RATTUS;

EID: 84871775620     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052522     Document Type: Article

References (57)

1. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, et al. (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc. and the Pulmonary Hypertension Association. J Am Coll Cardiol 53: 1573-1619.
2. Archer SL, Weir EK, Wilkins MR, (2010) Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 121: 2045-2066.
3. Michelakis ED, Wilkins MR, Rabinovitch M, (2008) Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation 118: 1486-1495.
4. Haddad F, Doyle R, Murphy DJ, Hunt SA, (2008) Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 117: 1717-1731.
5. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF, (2009) The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 135: 794-804.
6. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, et al. (2002) Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105: 85-92.
7. Gardin JM, Lauer MS, (2004) Left ventricular hypertrophy: the next treatable, silent killer? JAMA 292: 2396-2398.
8. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, et al. (2005) Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 171: 1292-1297.
9. Archer SL, Michelakis ED, (2009) Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 361: 1864-1871.
10. Piao L, Fang YH, Cadete VJ, Wietholt C, Urboniene D, et al. (2010) The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med (Berl) 88: 47-60.
11. Kusuhara M, Nagasaki K, Kimura K, Maass N, Manabe T, et al. (1999) Cloning of hexamethylene-bis-acetamide-inducible transcript, HEXIM1, in human vascular smooth muscle cells. Biomed Res 20: 273-279.
12. Zhou Q, Yik JH, (2006) The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol Mol Biol Rev 70: 646-659.
13. Peterlin BM, Price DH, (2006) Controlling the elongation phase of transcription with P-TEFb. Mol Cell 23: 297-305.
14. Wittmann BM, Fujinaga K, Deng H, Ogba N, Montano MM, (2005) The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1. Oncogene 24: 5576-5588.
15. Shimizu N, Ouchida R, Yoshikawa N, Hisada T, Watanabe H, et al. (2005) HEXIM1 forms a transcriptionally abortive complex with glucocorticoid receptor without involving 7SK RNA and positive transcription elongation factor b. Proc Natl Acad Sci U S A 102: 8555-8560.
16. Yoshikawa N, Shimizu N, Sano M, Ohnuma K, Iwata S, et al. (2008) Role of the hinge region of glucocorticoid receptor for HEXIM1-mediated transcriptional repression. Biochem Biophys Res Commun 371: 44-49.
17. Shimizu N, Yoshikawa N, Wada T, Handa H, Sano M, et al. (2008) Tissue- and context-dependent modulation of hormonal sensitivity of glucocorticoid-responsive genes by hexamethylene bisacetamide-inducible protein 1. Mol Endocrinol 22: 2609-2623.
18. Montano MM, Doughman YQ, Deng H, Chaplin L, Yang J, et al. (2008) Mutation of the HEXIM1 gene results in defects during heart and vascular development partly through downregulation of vascular endothelial growth factor. Circ Res 102: 415-422.
19. Ouchida R, Kusuhara M, Shimizu N, Hisada T, Makino Y, et al. (2003) Suppression of NF-kappaB-dependent gene expression by a hexamethylene bisacetamide-inducible protein HEXIM1 in human vascular smooth muscle cells. Genes Cells 8: 95-107.
20. Sano M, Abdellatif M, Oh H, Xie M, Bagella L, et al. (2002) Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med 8: 1310-1317.
21. Huang F, Wagner M, Siddiqui MA, (2004) Ablation of the CLP-1 gene leads to down-regulation of the HAND1 gene and abnormality of the left ventricle of the heart and fetal death. Mech Dev 121: 559-572.
22. Espinoza-Derout J, Wagner M, Shahmiri K, Mascareno E, Chaqour B, et al. (2007) Pivotal role of cardiac lineage protein-1 (CLP-1) in transcriptional elongation factor P-TEFb complex formation in cardiac hypertrophy. Cardiovasc Res 75: 129-138.
23. Espinoza-Derout J, Wagner M, Salciccioli L, Lazar JM, Bhaduri S, et al. (2009) Positive transcription elongation factor b activity in compensatory myocardial hypertrophy is regulated by cardiac lineage protein-1. Circ Res 104: 1347-1354.
24. Mascareno E, Galatioto J, Rozenberg I, Salciccioli L, Kamran H, et al. (2012) Cardiac lineage protein-1 (CLP-1) regulates cardiac remodeling via transcriptional modulation of diverse hypertrophic and fibrotic responses and angiotensin II-transforming growth factor β (TGF-β1) signaling axis. J Biol Chem 287: 13084-13093.
25. Ogba N, Doughman YQ, Chaplin LJ, Hu Y, Gargesha M, et al. (2010) HEXIM1 modulates vascular endothelial growth factor expression and function in breast epithelial cells and mammary gland. Oncogene 29: 3639-3649.
26. Mascareno E, Manukyan I, Das DK, Siddiqui MA, (2009) Down-regulation of cardiac lineage protein (CLP-1) expression in CLP-1+/- mice affords. J Cell Mol Med 13: 2744-2753.
27. Uzuki M, Sasano H, Muramatsu Y, Totsune K, Takahashi K, et al. (2001) Urocortin in the synovial tissue of patients with rheumatoid arthritis. Clin Sci (Lond) 100: 577-589.
28. Yokoyama C, Yabuki T, Shimonishi M, Wada M, Hatae T, et al. (2002) Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 106: 2397-2403.
29. Nishida K, Yamaguchi O, Hirotani S, Hikoso S, Higuchi Y, et al. (2004) p38alpha mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Mol Cell Biol 24: 10611-10620.
30. Shimizu N, Yoshikawa N, Ito N, Maruyama T, Suzuki Y, et al. (2011) Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab 13: 170-182.
31. Yoshikawa N, Nagasaki M, Sano M, Tokudome S, Ueno K, et al. (2009) Ligand-based gene expression profiling reveals novel roles of glucocorticoid receptor in cardiac metabolism. Am J Physiol Endocrinol Metab 296: E1363-1373.
32. Endo J, Sano M, Fujita J, Hayashida K, Yuasa S, et al. (2007) Bone marrow derived cells are involved in the pathogenesis of cardiac hypertrophy in response to pressure overload. Circulation 116: 1176-1184.
33. Unverferth DV, Baker PB, Swift SE, Chaffee R, Fetters JK, et al. (1986) Extent of myocardial fibrosis and cellular hypertrophy in dilated cardiomyopathy. Am J Cardiol 57: 816-820.
34. Huang F, Wagner M, Siddiqui MA, (2002) Structure, expression, and functional characterization of the mouse CLP-1 gene. Gene 292: 245-259.
35. Turano M, Napolitano G, Dulac C, Majello B, Bensaude O, et al. (2006) Increased HEXIM1 expression during erythroleukemia and neuroblastoma cell differentiation. J Cell Physiol 206: 603-610.
36. Contreras X, Barboric M, Lenasi T, Peterlin BM, (2007) HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog 3: 1459-1469.
37. Ritchie RH, Rosenkranz AC, Huynh LP, Stephenson T, Kaye DM, et al. (2004) Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent signaling. Am J Physiol Heart Circ Physiol 287: H1179-1185.
38. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, et al. (2004) Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 94: 1101-1108.
39. Sugden PH, (2003) An overview of endothelin signaling in the cardiac myocyte. J Mol Cell Cardiol 35: 871-886.
40. Wang L, Proud CG, (2002) Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes. Circ Res 91: 821-829.
41. Rohini A, Agrawal N, Koyani CN, Singh R, (2010) Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 61: 269-280.
42. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF, (2009) Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297: L1013-1032.
43. Mizuno S, Bogaard HJ, Kraskauskas D, Alhussaini A, Gomez-Arroyo J, et al. (2011) p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am J Physiol Lung Cell Mol Physiol 300: L753-761.
44. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ, (2008) Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 117: 1436-1448.
45. Roeleveld RJ, Vonk-Noordegraaf A, Marcus JT, Bronzwaer JG, Marques KM, et al. (2004) Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. Chest 125: 572-579.
46. Obata H, Sakai Y, Ohnishi S, Takeshita S, Mori H, et al. (2008) Single injection of a sustained-release prostacyclin analog improves pulmonary hypertension in rats. Am J Respir Crit Care Med 177: 195-201.
47. Krenz M, Robbins J, (2004) Impact of beta-myosin heavy chain expression on cardiac function during stress. J Am Coll Cardiol 44: 2390-2397.
48. Akazawa H, Komuro I, (2003) Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res 92: 1079-1088.
49. Liang Q, Molkentin JD, (2002) Divergent signaling pathways converge on GATA4 to regulate cardiac hypertrophic gene expression. J Mol Cell Cardiol 34: 611-616.
50. Yamashita K, Discher DJ, Hu J, Bishopric NH, Webster KA, (2001) Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. J Biol Chem 276: 12645-12653.
51. Park AM, Wong CM, Jelinkova L, Liu L, Nagase H, et al. (2010) Pulmonary hypertension-induced GATA4 activation in the right ventricle. Hypertension 56: 1145-1151.
52. Stewart DJ, Levy RD, Cernacek P, Langleben D, (1991) Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114: 464-469.
53. Filep JG, Bodolay E, Sipka S, Gyimesi E, Csipö I, et al. (1995) Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease. Circulation 92: 2969-2974.
54. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, et al. (1995) Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 26: 1581-1585.
55. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, et al. (1999) Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159: 1925-1932.
56. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54: S78-84.
57. Grainger DJ, Hesketh TR, Weissberg PL, Metcalfe JC, (1992) Hexamethylenebisacetamide selectively inhibits the proliferation of human and rat vascular smooth-muscle cells. Biochem J 283 (Pt 2): 403-408.